INFIXION BIOSCIENCE, INC.
Biotech · Private
Antisense oligonucleotide (ASO) therapeutics targeting miRNA regulators of NF1 protein to treat neurofibromatosis type 1
- Grants
- $1.7M
- 11 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201920202021202220232024
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Increasing NF1 Expression as a Treatment for NF1 Haploinsufficiency | $299,503 | |
| Federal grant | Department of Health and Human Services · Phase I · Increasing NF1 Expression as a Treatment for NF1 Haploinsufficiency | $52,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Increasing NF1 Expression as a Treatment for NF1 Haploinsufficiency | $150,794 | |
| Federal grant | Department of Health and Human Services · Phase I · Increasing NF1 Expression as a Treatment for NF1 Haploinsufficiency | $53,803 | |
| Federal grant | Department of Health and Human Services · Phase I · Inhibition of NF1 Protein Degradation as a Treatment for NF1 Haploinsufficiency | $338,722 | |
| Federal grant | Department of Health and Human Services · Phase I · Steric-blocking AntiSense Oligonucleotide (ASO) Discovery to Selectively Correct NF1 Haploinsufficiency | $339,520 | |
| Federal grant | Department of Health and Human Services · Phase I · Inhibition of NF1 Protein Degradation as a Treatment for NF1 Haploinsufficiency | $143,781 | |
| Federal grant | Department of Health and Human Services · Phase I · Steric-blocking AntiSense Oligonucleotide (ASO) Discovery to Selectively Correct NF1 Haploinsufficiency | $38,836 | |
| Federal grant | Department of Health and Human Services · Phase I · Steric-blocking AntiSense Oligonucleotide (ASO) Discovery to Selectively Correct NF1 Haploinsufficiency | $154,078 | |
| Federal grant | Department of Health and Human Services · Phase I · Steric-blocking AntiSense Oligonucleotide (ASO) Discovery to Selectively Correct NF1 Haploinsufficiency | $56,254 | |
| Federal grant | Department of Health and Human Services · Phase I · Steric-blocking AntiSense Oligonucleotide (ASO) Discovery to Selectively Correct NF1 Haploinsufficiency | $100,465 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2340 | Tallac Therapeutics, Inc. | — | $21M |
| 2341 | AION Healthspan, Inc. | — | $2.9M |
| 2342 | Avm Biotechnology, LLC | — | $5.8M |
| 2343 | INFIXION BIOSCIENCE, INC. | — | — |
| 2344 | BioLeap, Inc. | — | $5.0M |
| 2345 | GENOPLAN INC. | — | $4.2M |
| 2346 | LifeMine Therapeutics | — | $30M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.